Evidence map›Paper›PMID 29743334›Full record

ArticleBMJ open2018

Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.

Ragada El-Damanawi, Michael Lee, Tess Harris, Laura B Mader, Simon Bond, Holly Pavey, Richard N Sandford, Ian B Wilkinson, Alison Burrows, Przemyslaw Woznowski and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02933268 (Determining Feasibility of Randomisation to High vs ad Libitum Water Intake in Polycystic Kidney Disease), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02933268 nacompletednot on this map

Determining Feasibility of Randomisation to High vs ad Libitum Water Intake in Polycystic Kidney Disease: The DRINK Randomised Feasibility Trial

TypeinterventionalSponsorCambridge University Hospitals NHS Foundation TrustRan2016 to 2018Enrolled42ConditionsAutosomal Dominant Polycystic Kidney DiseaseArmsHigh water intake, Ad libitum water intake
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Assessing the engagement of children and families in selecting patient-reported outcomes (PROs) and developing their measures: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ragada El-DamanawiDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.
Michael LeeDivision of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.
Tess HarrisPKD Charity, London, UK.
Laura B MaderCambridge Clinical Trials Unit, Cambridge, UK.
Simon BondCambridge Clinical Trials Unit, Cambridge, UK.
Holly PaveyCambridge Clinical Trials Unit, Cambridge, UK.
Richard N SandfordDepartment of Medical Genetics, University of Cambridge, Cambridge, UK.
Ian B WilkinsonDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.
Alison BurrowsUniversity of Bristol, Bristol, UK.
Przemyslaw WoznowskiUniversity of Bristol, Bristol, UK.
Yoav Ben-ShlomoUniversity of Bristol, Bristol, UK.
Fiona E Karet FranklDepartment of Medical Genetics, University of Cambridge, Cambridge, UK.
Thomas F HiemstraDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.
MRC Clinical Trials Unit at UCL · GBUniversity of Cambridge · GBUniversity of Bristol · GBNational Patient Safety Foundation · US

Funding

British Heart Foundation FS/07/001/21990British Heart Foundation FS/12/33/29561British Heart Foundation FS/12/8/29377Medical Research Council MC_UU_00002/3
6 · The paper itself

Abstract

introductionVasopressin stimulates cyst growth in autosomal dominant polycystic kidney disease (ADPKD) leading to enlarged kidneys, hypertension and renal failure. Vasopressin receptor blockade slows disease progression. Physiological suppression of vasopressin secretion through high water (HW) intake could achieve a similar effect, necessitating a definitive large-scale trial of HW intake in ADPKD. The objective of the DRINK trial is to answer the key design and feasibility questions required to deliver a successful definitive water intake trial. METHODS AND ANALYSIS: We describe the design of a single-centre, open-label, prospective, randomised controlled trial. The " ETHICS AND DISSEMINATION: Ethical approval was awarded by the East of England Essex Research Ethics Committee (16/EE/0026). The results of DRINK will be submitted to peer-reviewed journals, and presented to patients via the PKD Charity. TRIAL REGISTRATION NUMBER: NCT02933268 and ISCRTN16794957.

Indexed as

DrinkingFluid TherapyHypertensionPolycystic Kidney, Autosomal DominantRenal InsufficiencyFeasibility StudiesGlomerular Filtration RateHumansOsmolar ConcentrationPatient Acceptance of Health CareProspective StudiesQuality of LifeRandomized Controlled Trials as TopicResearch DesignVasopressinsVasopressinsautosomal dominant polcystic kidney diseasefeasibilityosmolalityurine specific gravityvasopressinwater

Identifiers

PMID29743334
PMCPMC5942404
OpenAlexW2808365808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.